Skip to content
DataLookout
Menu

PLS-NEO-RCCNCT07922915

Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Objective Response Rate (ORR)
Timeframe: From baseline through completion of neoadjuvant treatment, approximately 18 weeks.

Secondary (5)

Major Pathological Response (MPR) Rate
Partial Nephrectomy Success Rate
R0 Resection Rate
Surgical Complications
Adverse Events

Arms and interventions

Pucotenlimab Plus Lenvatinib and SBRTExperimental

Participants will receive neoadjuvant pucotenlimab 200 mg intravenously every 3 weeks for up to six cycles and lenvatinib 12 mg orally once daily. SBRT at 40 Gy in five fractions will be delivered to the primary renal tumor after cycle 2 and before cycle 4. Surgery is planned after neoadjuvant treatment, with partial nephrectomy preferred when feasible.

Drugs: Pucotenlimab, Lenvatinib

Radiation: Stereotactic Body Radiotherapy